Skip to main content

Analysts cheer ‘surprisingly positive’ AstraZeneca U.S. trial data

Jefferies healthcare analyst Peter Welford said the analysis of the AstraZeneca shot, published Monday, was better than expected.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.